Lung cancer is the leader malignancy worldwide accounting 1.5 millions of deaths every
year. In the United States the 5 year-overall survival is less than 20% for all the newly …

Molecularly targeted therapies and immune checkpoint inhibitors have markedly improved
the therapeutic management of advanced lung cancer. However, it still remains the leading …

Immune checkpoint inhibitors have significantly improved overall survival with an acceptable
safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. …

Human endogenous retroviruses (HERVs) are retroviruses that infected human genome
millions of years ago and have persisted throughout human evolution. About 8% of our genome …

Background The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) in EGFR-mutant non–small cell lung cancer (NSCLC) is limited by adaptive …

Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated
non-small-cell lung cancer (NSCLC) patients. We investigated the association …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths
worldwide. The majority of patients are diagnosed in advanced disease stage. Bone …

Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly
based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination …

The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase inhibitors (…

75 Cancer Biol Med Vol 12, No 2 June 2015 this committee concluded that the study
reached its endpoint, demonstrating superior overall survival with nivolumab compared with …